Direct and indirect costs of COPD and its comorbidities: Results from the German COSYCONET study

Respiratory Medicine

Volumn 111, Issue , 2016, Pages 39-46

  Wacker, M E ^a   Jorres R A ^b   Schulz, H ^a   Heinrich, J ^a   Karrasch, S ^a,b,c   Karch, A ^d   Koch, A ^d   Peters, A ^a   Leidl, R ^a,e   Vogelmeier, C ^f   Holle, R ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

^f UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Comorbidity; COPD; Cost; Healthcare

Indexed keywords

ABSENTEEISM; ADULT; AGED; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; COST; DIRECT COST; FEMALE; HEALTH CARE UTILIZATION; HUMAN; INDIRECT COST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RETIREMENT; SMOKING; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; ECONOMICS; GERMANY; HEALTH CARE COST; MULTICENTER STUDY; PATIENT ATTITUDE; PROSPECTIVE STUDY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; VERY ELDERLY;

ABSENTEEISM; ADULT; AGED; AGED, 80 AND OVER; COMORBIDITY; CROSS-SECTIONAL STUDIES; FEMALE; GERMANY; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84959549207     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2015.12.001     Document Type: Article

References (37)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (Update 2015). Available from: http://www.goldcopd.org/.
2. S.H. Landis, H. Muellerova, D.M. Mannino, A.M. Menezes, M.K. Han, T. van der Molen, M. Ichinose, Z. Aisanov, Y.M. Oh, and K.J. Davis Continuing to confront COPD international patient survey: methods, COPD prevalence, and disease burden in 2012-2013 Int. J. Chron. Obstruct. Pulmon. Dis. 9 2014 597 611
3. L.E. Vanfleteren, M.A. Spruit, M. Groenen, S. Gaffron, V.P. van Empel, P.L. Bruijnzeel, E.P. Rutten, J. Op 't Roodt, E.F. Wouters, and F.M. Franssen Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease Am. J. Respir. Crit. Care Med. 187 2013 728 735
4. M.C. Smith, and J.P. Wrobel Epidemiology and clinical impact of major comorbidities in patients with COPD Int. J. Chron. Obstruct. Pulmon. Dis. 9 2014 871 888
5. N. Putcha, M.A. Puhan, N.N. Hansel, M.B. Drummond, and C.M. Boyd Impact of co-morbidities on self-rated health in self-reported COPD: an analysis of NHANES 2001-2008 COPD 10 2013 324 332
6. P. Menn, N. Weber, and R. Holle Health-related quality of life in patients with severe COPD hospitalized for exacerbations - comparing EQ-5D, SF-12 and SGRQ Health Qual. Life Outcomes 8 2010 39
7. M.B. Huber, M.E. Wacker, C.F. Vogelmeier, and R. Leidl Comorbid influences on generic health-related quality of life in COPD: a systematic review PLoS One 10 2015 e0132670
8. J. Gibson, L. Loddenkemper, Y. Sibille, and B. Lundbäck The European Lung White Book 2013 European Respiratory Society Sheffield
9. F. Kirsch, C.M. Teuner, P. Menn, and R. Leidl Costs of illness for asthma and COPD in adults in Germany Gesundheitswesen 75 2013 413 423
10. T. Simon-Tuval, S.M. Scharf, N. Maimon, B.J. Bernhard-Scharf, H. Reuveni, and A. Tarasiuk Determinants of elevated healthcare utilization in patients with COPD Respir. Res. 12 2011 7
11. D.M. Mannino, K. Higuchi, T.C. Yu, H. Zhou, Y. Li, H. Tian, and K. Suh Economic burden of chronic obstructive pulmonary disease by presence of comorbidities Chest 148 2015 138 150
12. F. Baty, P.M. Putora, B. Isenring, T. Blum, and M. Brutsche Comorbidities and burden of COPD: a population based case-control study PLoS One 8 2013 e63285
13. M.B. Huber, M.E. Wacker, C.F. Vogelmeier, and R. Leidl Excess costs of comorbidities in chronic obstructive pulmonary disease: a systematic review PLoS One 10 2015 e0123292
14. K. Srivastava, D. Thakur, S. Sharma, and Y.S. Punekar Systematic review of humanistic and economic burden of symptomatic chronic obstructive pulmonary disease PharmacoEconomics 33 2015 467 488
15. R.A. Jorres, T. Welte, R. Bals, A. Koch, M. Schnoor, and C. Vogelmeier Systemic manifestations and comorbidities in patients with chronic obstructive pulmonary disease (COPD) and their effect on clinical state and course of the disease-an overview of the cohort study COSYCONET Dtsch. Med. Wochenschr. 135 2010 446 449
16. R. Holle, M. Happich, H. Lowel, and H.E. Wichmann KORA-a research platform for population based health research Gesundheitswesen 67 Suppl 1 2005 S19 S25
17. A. Peters, A. Doring, K.H. Ladwig, C. Meisinger, B. Linkohr, C. Autenrieth, S.E. Baumeister, J. Behr, A. Bergner, H. Bickel, and et al. Multimorbidity and successful aging: the population-based KORA-Age study Z. Gerontol. Geriatr. 44 Suppl 2 2011 41 54
18. M.R. Miller, J. Hankinson, V. Brusasco, F. Burgos, R. Casaburi, A. Coates, R. Crapo, P. Enright, C.P. van der Grinten, P. Gustafsson, and et al. Standardisation of spirometry Eur. Respir. J. 26 2005 319 338
19. P.H. Quanjer, S. Stanojevic, T.J. Cole, X. Baur, G.L. Hall, B.H. Culver, P.L. Enright, J.L. Hankinson, M.S.M. Ip, J. Zheng, and et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations Eur. Respir. J. 40 2012 1324 1343
20. J.O. Bock, C. Brettschneider, H. Seidl, D. Bowles, R. Holle, W. Greiner, and H.H. Konig Calculation of standardised unit costs from a societal perspective for health economic evaluation Gesundheitswesen 77 2015 53 61
21. WHO Collaborating Centre for Drug Statistics Methodology Guidelines for ATC Classification and DDD Assignment 2010 Oslo 2009
22. [Research Institute of the AOK], Available from: http://wido.de/arzneimittel.html.
23. Federal Statistical Office National Accounts - Compensation per Employee 2013 Gross Wages and Salaries Wiesbaden
24. Institute for Employment Research (IAB) of the German Federal Employment Agency (BA) 2014 IAB Brief Reports Nr. 18. Nuremberg
25. J.M. Graf von der Schulenburg, W. Greiner, F. Jost, N. Klusen, M. Kubin, R. Leidl, T. Mittendorf, H. Rebscher, O. Schoeffski, C. Vauth, and et al. German recommendations on health economic evaluation: third and updated version of the Hanover Consensus Value Health 11 2008 539 544
26. M.A. Koopmanschap, F.F.H. Rutten, B.M. van Ineveld, and L. van Roijen The friction cost method for measuring indirect costs of disease J. Health Econ. 14 1995 171 189
27. B.I. Graubard, and E.L. Korn Predictive margins with survey data Biometrics 55 1999 652 659
28. P. Menn, J. Heinrich, R.M. Huber, R.A. Jorres, J. John, S. Karrasch, A. Peters, H. Schulz, and R. Holle Direct medical costs of COPD - an excess cost approach based on two population-based studies Respir. Med. 106 2012 540 548
29. S.A. Jansson, A. Lindberg, A. Ericsson, S. Borg, E. Ronmark, F. Andersson, and B. Lundback Cost differences for COPD with and without physician-diagnosis COPD 2 2005 427 434
30. S.A. Jansson, H. Backman, E. Ronmark, B. Lundback, and A. Lindberg Hospitalization due to co-morbid conditions is the main cost driver among subjects with COPD - a report from the population-based OLIN COPD Study COPD 12 2014 381 389
31. A.S. Gershon, J. Guan, J.C. Victor, R. Goldstein, and T. To Quantifying health services use for chronic obstructive pulmonary disease Am. J. Respir. Crit. Care Med. 187 2013 596 601
32. E.S. Ford, L.B. Murphy, O. Khavjou, W.H. Giles, J.B. Holt, and J.B. Croft Total and state-specific medical and absenteeism costs of COPD among adults aged ≥18 years in the United States for 2010 and projections through 2020 Chest 147 2015 31 45
33. M. Erdal, A. Johannessen, J.E. Askildsen, T. Eagan, A. Gulsvik, and R. Gronseth Productivity losses in chronic obstructive pulmonary disease: a population-based survey BMJ Open Respir. Res. 1 2014 e000049
34. J.G. Patel, S.P. Nagar, and A.A. Dalal Indirect costs in chronic obstructive pulmonary disease: a review of the economic burden on employers and individuals in the united states Int. J. Chron. Obstruct. Pulmon. Dis. 9 2014 289 300
35. H. Seidl, C. Meisinger, R. Wende, and R. Holle Empirical analysis shows reduced cost data collection may be an efficient method in economic clinical trials BMC Health Serv. Res. 12 2012 318
36. C. Evans, and B. Crawford Patient self-reports in pharmacoeconomic studies. Their use and impact on study validity Pharmacoecon 15 1999 241 256
37. K. Schnell, C. Weiss, T. Lee, J. Krishnan, B. Leff, J. Wolff, and C. Boyd The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999-2008 BMC Pulm. Med. 12 2012 26